Trevi Reports Q3 Results; Advances Haduvio Programs Across Three Chronic Cough Indications
Trevi Therapeutics (TRVI) reported Q3 2026 results, with R&D expenses up to $19.1M and net loss of $21.5M. The company advanced its Haduvio programs for chronic cough, initiating a Phase 3 trial and planning a Phase 2 study. Trevi expects cash to fund operations into 2030. Haduvio is being tested for IPF, non-IPF ILD, and refractory chronic cough, with key trial results expected in 2027-2028.
How this was made
The 30-second read
Why it matters
The Q3 earnings beat expectations on R&D spend and cash position, while the trial updates provide a forward‑looking catalyst that could drive the stock higher if data are positive.
Market read
First‑time disclosure of Phase 3 trial start and FDA meeting makes this a material news event for TRVI, with potential short‑term price impact.
What to watch
Cash runway of $299M may limit future financing needs, reducing dilution risk.
Background
Trevi Therapeutics is a clinical‑stage company developing Haduvio, an oral nalbuphine extended‑release therapy for chronic cough across IPF, non‑IPF ILD, and refractory indications.
Ticker impact
Trevi Therapeutics reported Q3 2026 results and announced initiation of Phase 3 OCEAN-2 trial and a positive FDA meeting for its non‑IPF ILD program.
likely modest upside as investors price in progress on the Haduvio program
First disclosure of Phase 3 start and FDA meeting reduces development risk, supporting near‑term demand for the stock.
Market effects
Advances in chronic cough therapeutics may lift sentiment for the broader biotech sector focused on respiratory diseases.
U.S. biotech investors may see a slight boost; limited impact outside the sector.
Minimal global effect beyond niche biotech investors.
Counterpoint
If trial enrollment slows or data disappoint, the stock could face pressure despite current optimism.
Key entities
- ExecutiveJennifer Good
CEO of Trevi Therapeutics, quoted on trial progress and FDA alignment.
